Page last updated: 2024-11-12

galidesivir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10445549
CHEMBL ID1236524
SCHEMBL ID12468816
MeSH IDM0507176

Synonyms (35)

Synonym
bcx4430
immucillin a
CHEMBL1236524
galidesivir
bcx-4430
ua2 ,
3,4-pyrrolidinediol,2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-2s,3s,4r,5r
SCHEMBL12468816
(2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
AMFDITJFBUXZQN-KUBHLMPHSA-N
CS-3779
unii-olf97f86a7
olf97f86a7 ,
immucillin-a
imma cpd
249503-25-1
3,4-pyrrolidinediol, 2-(4-amino-5h-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)-, (2s,3s,4r,5r)-
galidesivir [inn]
galidesivir [who-dd]
HY-18649A
bcx4430 (freebase)
AKOS027252693
NCGC00485882-01
DB11676
bcx4430 freebase
bcx 4430 free base
P14655
MS-23748
A900809
galidesivir; bcx4430; bcx 4430; bcx-4430;(2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
bcx4430freebase
bdbm50513995
(2s,3s,4r,5r)-2-{4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl}-5-(hydroxymethyl)pyrrolidine-3,4-diol
EX-A6295
gtpl11920

Research Excerpts

Overview

Galidesivir (BCX4430) is an adenosine nucleoside analog. It is broadly active in cell culture against several RNA viruses of various families. It can attenuate flavivirus replication in cell-based assays and animal models of infection.

ExcerptReferenceRelevance
"Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. "( An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
Babu, YS; Demarest, JF; Gowen, BB; Julander, JG; Mathis, A; Taylor, R; Walling, DM, 2021
)
2.36
"Galidesivir is a broad-spectrum antiviral compound with demonstrated in vitro and in vivo efficacy against several RNA viruses of public health concern, including those causing yellow fever, Ebola, Marburg, and Rift Valley fever."( Activity of Galidesivir in a Hamster Model of SARS-CoV-2.
Babu, YS; Bielefeldt-Ohmann, H; Bowen, R; Demarest, JF; DeSpirito, M; Hartwig, A; Mathis, A; Taylor, R; Walling, DM, 2021
)
1.72
"Galidesivir (BCX4430) is an adenosine nucleoside analog broadly active in cell culture against multiple RNA virus families, and active in animal models of viral diseases associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever. "( Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects.
Collins, D; Dobo, S; Mathis, A; Sheridan, WP; Taylor, R; Walling, DM, 2022
)
2.4
"Galidesivir is an adenosine nucleoside analog that can attenuate flavivirus replication in cell-based assays and animal models of infection."( Galidesivir Triphosphate Promotes Stalling of Dengue-2 Virus Polymerase Immediately Prior to Incorporation.
Bulloch, EMM; Deshpande, S; Evans, GB; Harris, LD; Huo, W; Kingston, RL; Shrestha, R; Sparrow, K; Wood, JM, 2023
)
3.07

Treatment

ExcerptReferenceRelevance
"Treatment with galidesivir reduced lung pathology in infected animals compared with untreated controls when treatment was initiated 24 h prior to infection."( Activity of Galidesivir in a Hamster Model of SARS-CoV-2.
Babu, YS; Bielefeldt-Ohmann, H; Bowen, R; Demarest, JF; DeSpirito, M; Hartwig, A; Mathis, A; Taylor, R; Walling, DM, 2021
)
1.34

Toxicity

ExcerptReferenceRelevance
" No fatal events or related serious adverse events were reported."( Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects.
Collins, D; Dobo, S; Mathis, A; Sheridan, WP; Taylor, R; Walling, DM, 2022
)
0.96

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we review the pharmacokinetic and pharmacodynamic information presently available for these drugs, using data obtained in healthy volunteers for pharmacokinetics and data obtained in human clinical trials or animal models for pharmacodynamics."( Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
de Lamballerie, X; Guedj, J; Madelain, V; Mentré, F; Nguyen, TH; Olivo, A; Taburet, AM, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Significant improvement in survival was observed after treatment with BCX4430 at 4 mg/kg of body weight per day dosed intraperitoneally (i."( BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.
Babu, YS; Bantia, S; Julander, JG; Kotian, P; Minning, DM; Morrey, JD; Sheridan, WP; Smee, DF; Taubenheim, BR, 2014
)
0.4
" Effective rabies antivirals for therapeutic use need to be molecules that can be dosed into the cerebrospinal fluid and that rapidly and potently block ongoing virus replication and as such stop the further spread of the virus."( The path towards effective antivirals against rabies.
Jochmans, D; Neyts, J, 2019
)
0.51
" Study 1 evaluated the safety and tolerability of IM galidesivir over single day dosing, single day dosing ± lidocaine, and 7-day dosing with lidocaine."( Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects.
Collins, D; Dobo, S; Mathis, A; Sheridan, WP; Taylor, R; Walling, DM, 2022
)
1.21
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Purine nucleoside phosphorylaseHomo sapiens (human)Ki0.03300.00000.52897.0000AID1571176
Purine nucleoside phosphorylase Bos taurus (cattle)Ki2.60000.00000.53072.7000AID1571175
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
urate biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of T cell proliferationPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationPurine nucleoside phosphorylaseHomo sapiens (human)
allantoin metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nucleobase-containing compound metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyinosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyadenosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylaseHomo sapiens (human)
IMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nicotinamide riboside catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
immune responsePurine nucleoside phosphorylaseHomo sapiens (human)
nucleotide biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
response to xenobiotic stimulusPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of interleukin-2 productionPurine nucleoside phosphorylaseHomo sapiens (human)
purine-containing compound salvagePurine nucleoside phosphorylaseHomo sapiens (human)
dAMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
nucleoside bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine nucleobase bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
phosphate ion bindingPurine nucleoside phosphorylaseHomo sapiens (human)
identical protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
guanosine phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylase Bos taurus (cattle)
guanosine phosphorylase activityPurine nucleoside phosphorylase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
cytosolPurine nucleoside phosphorylaseHomo sapiens (human)
secretory granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
extracellular exosomePurine nucleoside phosphorylaseHomo sapiens (human)
ficolin-1-rich granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1558290Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in human HuH7 cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1558296Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in human RD cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1845474Antiviral activity against SUDV Boniface by high-content image analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1558295Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in human Huh-7 cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1881744Half life in Sprague-Dawley rat liver microsomes at 30 mg/kg, IM measured up to 24 hrs2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1845473Antiviral activity against EBOV Kikwit by high-content image analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1558298Cytotoxicity against human RD cells2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1558294Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1571175Inhibition of bovine spleen PNP using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
The transition to magic bullets - transition state analogue drug design.
AID1845477Antiviral activity against SARS-Cov urbani by neutral red uptake analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1558289Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1881741Antiviral activity against SARS CoV-2 assessed as inhibition of virus-induced cytopathic effect by neutral red uptake assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1558291Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in human RD cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1558293Inhibition of RNA-dependent RNA polymerase in Zika virus Malaysian P 6-740 infected in human Huh-7 cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1558297Cytotoxicity against human HuH7 cells2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1845475Antiviral activity against MARV musoke by high-content image analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1845478Antiviral activity against MERS-CoV jordan N3 by high-content image analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1845476Antiviral activity against DENV2 new Guinea by neutral red uptake analysis2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID1881742Antiviral activity against MERS-CoV assessed as inhibition of virus-induced cytopathic effect by high-content image assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1558292Inhibition of RNA-dependent RNA polymerase in Zika virus Malaysian P 6-740 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1571176Inhibition of human PNP using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
The transition to magic bullets - transition state analogue drug design.
AID1881743Half life in mouse at 2 mg/kg, IM2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1558283Cytotoxicity against African green monkey Vero cells2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (8.89)29.6817
2010's25 (55.56)24.3611
2020's16 (35.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.92 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index5.36 (4.65)
Search Engine Demand Index42.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.17%)5.53%
Reviews14 (30.43%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (67.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19 [NCT03891420]Phase 124 participants (Actual)Interventional2020-04-09Terminated(stopped due to Sponsor decision to no longer pursue indications studied in this trial)
A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects [NCT03800173]Phase 132 participants (Actual)Interventional2018-12-10Completed
A Phase 1 Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BCX4430 Administered Via Intramuscular Injection (IM) in Healthy Subjects [NCT02319772]Phase 194 participants (Actual)Interventional2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03800173 (4) [back to overview]Galidesivir Renal Clearance
NCT03800173 (4) [back to overview]Plasma PK - Galidesivir Cmax (Maximum Observed Concentration of Drug)
NCT03800173 (4) [back to overview]Galidesivir Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.
NCT03800173 (4) [back to overview]Plasma PK - Galidesivir AUC (Area Under the Concentration vs. Time Curve)

Galidesivir Renal Clearance

Urine was collected from subjects over a 96 hour period per protocol, analyzed for galidesivir concentrations. Urine PK parameters including CLR (renal clearance of unchanged drug cumulatively over all collection intervals or in a specific interval) were estimated in SAS for Windows v9.4 or higher (SAS Institute, Inc.) based on the recorded urine concentrations and volumes. (NCT03800173)
Timeframe: Urine PK parameters are based on sampling over a 96 hour period.

InterventionL/hr (Geometric Mean)
5 mg/kg Galidesivir9.305
10 mg/kg Galidesivir11.66
15 mg/kg Galidesivir11.51
20 mg/kg Galidesivir7.131

[back to top]

Plasma PK - Galidesivir Cmax (Maximum Observed Concentration of Drug)

"Serial blood samples for PK assessment of plasma galidesivir were collected at the following time points:~Day 1 to Day 5: 0 hour (pre dose), halfway through the infusion (0.5 hour), 1 hour (end of the infusion), 1.25, 1.50, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, and 96 hours post dose.~Day 6 (+1 day), Day 8 (+1 day), Day 14 (± 1 day)~Day 21 (+2 days) or early termination.~Cmax for galidesivir was estimated using non compartmental methods with Phoenix® WinNonlin® v8.1 or higher (Certara, Inc.)." (NCT03800173)
Timeframe: Plasma PK parameters are based on sampling over a 21 day period

Interventionng/mL (Geometric Mean)
5 mg/kg Galidesivir5540
10 mg/kg Galidesivir10300
15 mg/kg Galidesivir17730
20 mg/kg Galidesivir20490

[back to top]

Galidesivir Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.

Any event reported on the subject's study record that occurred on or after the initiation of study drug was defined as treatment emergent (TEAE). (NCT03800173)
Timeframe: AEs were assessed and recorded from the time of signing the ICF through to the appropriate follow-up period, up to 23 days from IMP dosing on Day 1.

,,,,
Interventionparticipants (Number)
Subjects with at least 1 TEAENot related TEAEsRelated TEAEsMild TEAEModerate TEAESevere TEAESubjects with at least 1 SAESubject Discontinuation due to AE
10 mg/kg Galidesivir11010010
15 mg/kg Galidesivir42230110
20 mg/kg Galidesivir10110000
5 mg/kg Galidesivir00000000
Placebo22020000

[back to top]

Plasma PK - Galidesivir AUC (Area Under the Concentration vs. Time Curve)

"Serial blood samples for PK assessment of plasma galidesivir were collected at the following time points:~Day 1 to Day 5: 0 hour (pre dose), halfway through the infusion (0.5 hour), 1 hour (end of the infusion), 1.25, 1.50, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72, and 96 hours post dose.~Day 6 (+1 day), Day 8 (+1 day), Day 14 (± 1 day)~Day 21 (+2 days) or early termination.~AUC0-inf (AUC from time 0 extrapolated to infinite time) and AUC0-t (AUC from time 0 to time t, where t = the last quantifiable concentration) for galidesivir was estimated using non compartmental methods with Phoenix® WinNonlin® v8.1 or higher (Certara, Inc.)." (NCT03800173)
Timeframe: Plasma PK parameters are based on sampling over a 21 day period

,,,
Interventionng*h/mL (Geometric Mean)
AUC0-infAUC0-t
10 mg/kg Galidesivir3708032360
15 mg/kg Galidesivir6586059590
20 mg/kg Galidesivir8123073350
5 mg/kg Galidesivir2116017150

[back to top]